


See "Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies" on page 475-486.



Supplementary Fig. 6. Mean \pm SD serum ustekinumab concentrations ($\mu\text{g/mL}$) through week 8 (A) in UNITI-1 and (B) in UNITI-2 studies.